UCB and Parexel sign clinical services agreement

To drive innovation and accelerate development

Parexel International, a global biopharmaceutical services provider, has entered into a new alliance with UCB, in which it will provide support for the Belgian biopharmaceutical company’s clinical development services.

The organisation has been selected as one of two strategic partners by UCB, with the agreement effective for all of UCB's new clinical study programmes on a global basis.

UCB will benefit from Parexel's proven clinical processes through all phases of development, which are supported by its eClinical technology, as well as its expertise in regulatory affairs and commercialisation.

‘Parexel will assist UCB to improve efficiency and cost effectiveness, and support increased opportunity for innovation, collaboration and the continuous improvement of quality and services – helping us to deliver new medicines to patients worldwide,’ said Iris Loew-Friedrich, executive vice president and chief medical officer of UCB.

‘Parexel will be instrumental in helping UCB expand our global drug development activities including in Asia.’

Josef von Rickenbach, chairman and chief executive of Parexel, added: ‘We look forward to working collaboratively with UCB to deliver customised, innovative solutions to achieve their goals.’

Companies